Cancer Immunology, Immunotherapy

, Volume 56, Issue 11, pp 1711–1721

Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients

Authors

  • Carlyle Hamsher
    • Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health Sciences
  • Anna M. Smith
    • Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health Sciences
  • Zia A. Dehqanzada
    • Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health Sciences
  • Steven Khoo
    • Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health Sciences
  • Sathibalan Ponniah
    • Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health Sciences
  • George E. Peoples
    • Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health Sciences
    • Department of SurgeryBrooke Army Medical Center
    • Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health Sciences
    • Armed Forces Radiobiology Research InstituteUniformed Services University of the Health Sciences
Original Article

DOI: 10.1007/s00262-007-0314-3

Cite this article as:
Hamsher, C., Smith, A.M., Dehqanzada, Z.A. et al. Cancer Immunol Immunother (2007) 56: 1711. doi:10.1007/s00262-007-0314-3
  • 65 Views

Abstract

Humoral tumor-specific immunity has been investigated as a potential tool to identify tumor-associated antigens and evaluate cancer diagnosis and prognosis. Using SDS-PAGE and western blotting techniques we investigated the humoral immune response against tumor cell antigens in 36 breast cancer patients, 17 node-positive (NP) and 19 node-negative (NN). As a source of antigens, we prepared protein lysates from four breast cancer cell lines (AU565, BT474, MCF-7 and MDA-MB-231) which in vitro exhibit different features of invasion, estrogen receptor/progesterone receptor status and HER2/neu expression thereby potentially representing mild to aggressive forms of clinical disease. A higher number of immunocomplexes Ag–Ab were formed when serum from NN patients was immunoreacted against lysates from AU565 and MCF-7 in comparison to serum from NP patients (P < 0.01). BT474 cells were not a good antigenic source. MDA-MB-231 cells could not significantly discriminate between NN and NP patients since both groups showed higher amounts of reactivity against the lysate. However, comparative analysis of protein preparations purified from MCF-7 and MDA-MB-231 cells and immunodetected concomitantly with the same serum samples showed that serum from patients with cancers with worse prognosis (stage, nodality, HER2/neu and hormonal status) reacted more intensely to proteins purified from the relatively more invasive cell line MDA-MB-231 compared to MCF-7. These findings suggest that the study of serum antibody reactivity to antigens purified from breast cancer cell lines with different invasive properties should be further investigated for its potential in providing beneficial prognostic information in breast cancer.

Keywords

Breast cancerSerum antibodyImmunoreactivityTumor cell lysates

Abbreviations

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel

NP

Node-positive

NN

Node-negative

HER2/neu

Human epidermal growth factor receptor/neu

cDNA

Complementary deoxyribonucleic acid

SEREX

Serological expression cloning

SERPA

Serological proteome analysis

IR

Immunoreactivity

ELISA

Enzyme-linked immunosorbent assay

IgG

Immunoglobulin

TI

Total immunoreactivity

ANOVA

Analysis of variance

SE

Standard error

IP

Immunoreactivity pattern

Ag-Ab

Antigen-antibody

TIP

Total immunoreactivity pattern

Copyright information

© Springer-Verlag 2007